Browse
 
Dahl Chase Folders

BRAF Mutation Assay

Reference Number: AA-00312


 

SECTION EIGHT

Dahl-Chase Diagnostic Services

MOLECULAR PATHOLOGY TESTING

BRAF V600E MUTATION ASSAY

 

Clinical Significance:

 

BRAF V600E mutation analysis is useful in determining patient eligibility for targeted EGFR inhibitor therapy for metastatic colorectal carcinoma.  While BRAF mutation testing is currently not viewed as mandatory by the National Comprehensive Cancer Network (NCCN), the most recent guidelines state that patients with a BRAF V600E mutation appear unlikely to benefit from anti-EGFR monoclonal antibodies.  Therefore, our laboratory will typically reflex KRAS wild-type carcinomas to BRAF mutation testing.  There is no need to test patients with KRAS mutation for BRAF mutation because evidence suggests that these two mutations are mutually exclusive. 

 

Specimen Requirements and Collection:

Formalin fixed tissue containing a sufficient amount of tumor (generally at least several mm of tumor tissue submitted in the tissue block).  The BRAF V600E  test utilized by our laboratory will detect mutations as long as they constitute at least 10% of the DNA sample mix.

 

Forms:

Molecular Pathology requisition form

 

Transport:

Send paraffin block containing tumor at room temperature

 

Reference Range:

BRAF V600E mutation not detected = negative result

BRAF V600E mutation detected = positive result

 

 

CPT codes:

88381, 81275, 81403, G0452

 

 

 

Test reported:

Results are reported within 7-10 days